For individuals, friends and families who are looking to connect during life's challenging times. Share personal experiences, evaluate information and get support during times of need, illness, treatment or recovery.
Sponsored Links
Main Menu
Community
Treatment
Understand
- Where to Start
- What is Lymphoma?
- The Lymphatic System
- Lymphoma Symptoms
- Lymphoma Causes
- Lymphoma Prognosis
- Refractory/Relapsed Lymphoma
Non-Hodgkin's Lymphoma
Hodgkin's Disease
Surviving Lymphoma
Lymphoma and Pets
More
Trials to Continue on Promising Drug for some Lymphoma Patients
-
Call (877) 399-6937 or click here to learn more about Cancer Treatment options.
An important clinical trial for patients with relapsed or refractory Hodgkin lymphoma who have previously been given autologous stem cell transplants is scheduled to begin in early 2009 under the auspices of Seattle Genetics (www.seagen.com). They will enroll 100 patients in the US, Canada and Europe.
The trial will test the efficacy of a drug currently called SGN-35, an antibody-drug conjugate (ADC) that, once it gets inside CD30-expressing tumor cells, releases monomethyl auristatin E (MMAE), which kills those cells.
They also plan to begin a phase II study of SGN-35 in early 2009 for patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL).
The President and CEO of Seattle Genetics told therapeuticsdaily.com, “The data thus far from both of our phase I trials of SGN-35 have exceeded our expectations … suggesting that this agent may address a substantial unmet medical need in patients with relapsed or refractory Hodgkin lymphoma.”
Provided the trials go well, Seattle Genetics intends to submit an accelerated new drug application to the FDA for SGN-35 in 2011.
The trial will test the efficacy of a drug currently called SGN-35, an antibody-drug conjugate (ADC) that, once it gets inside CD30-expressing tumor cells, releases monomethyl auristatin E (MMAE), which kills those cells.
They also plan to begin a phase II study of SGN-35 in early 2009 for patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL).
The President and CEO of Seattle Genetics told therapeuticsdaily.com, “The data thus far from both of our phase I trials of SGN-35 have exceeded our expectations … suggesting that this agent may address a substantial unmet medical need in patients with relapsed or refractory Hodgkin lymphoma.”
Provided the trials go well, Seattle Genetics intends to submit an accelerated new drug application to the FDA for SGN-35 in 2011.
-
Call (877) 399-6937 or click here to learn more about Cancer Treatment options.
Support Groups
Find a Treatment Facility Near You
Click on a state below to find Lymphoma treatment options that could be right for you.
Select a State Below
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- Florida
- Georgia
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
The information provided on the Lymphoma Information Network is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational and educational purposes. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Neither the owners or employees of LymphomaInfo.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
Sponsored Links
LymphomaInfo Social
SupportGroups.com
SupportGroups.com provides a support network for those dealing with cancer and other life's challenges. Click on the following links to get the support in a confidential, caring environment.
Follow LymphomaInfo.net on:
Facebook:
Twitter: